Abstract:New, safe and effective drugs are urgently needed to treat and control malaria and tuberculosis, which affect millions of people annually. However, financial return on investment in the poor settings where these diseases are mostly prevalent is very minimal to support market-driven drug discovery and development. Moreover, the imminent loss of therapeutic lifespan of existing therapies due to evolution and spread of drug resistance further compounds the urgency to identify novel effective drugs. However, the advent of new public-private partnerships focused on tropical diseases and the recent release of large data sets by pharmaceutical companies on antimalarial and antituberculosis compounds derived from phenotypic whole cell high throughput screening have spurred renewed interest and opened new frontiers in malaria and tuberculosis drug discovery. This Account recaps the existing challenges facing antimalarial and antituberculosis drug discovery, including limitations associated with experimental animal models as well as biological complexities intrinsic to the causative pathogens. We enlist various highlights from a body of work within our research group aimed at identifying and characterizing new chemical leads, and navigating these challenges to contribute toward the global drug discovery and development pipeline in malaria and tuberculosis. We describe a catalogue of in-house efforts toward deriving safe and efficacious preclinical drug development candidates via cell-based medicinal chemistry optimization of phenotypic whole-cell medium and high throughput screening hits sourced from various small molecule chemical libraries. We also provide an appraisal of target-based screening, as invoked in our laboratory for mechanistic evaluation of the hits generated, with particular focus on the enzymes within the de novo pyrimidine biosynthetic and hemoglobin degradation pathways, the latter constituting a heme detoxification process and an associated cysteine protease-mediated hydrolysis of hemoglobin. We further expound on the recombinant enzyme assays, heme fractionation experiments, and genomic and chemoproteomic methods that we employed to identify Plasmodium falciparum falcipain 2 (PfFP2), hemozoin formation, phosphatidylinositol 4-kinase (PfPI4K) and Mycobacterium tuberculosis cytochrome bc1 complex as the targets of the antimalarial chalcones, pyrido[1,2-a]benzimidazoles, aminopyridines, and antimycobacterial pyrrolo[3,4-c]pyridine-1,3(2H)-diones, respectively. In conclusion, we argue for the expansion of chemical space through exploitation of privileged natural product scaffolds and diversity-oriented synthesis, as well as the broadening of druggable spaces by exploiting available protein crystal structures, -omics data, and bioinformatics infrastructure to explore hitherto untargeted spaces like lipid metabolism and protein kinases in P. falciparum. Finally, we audit the merits of both target-based and whole-cell phenotypic screening in steering antimalarial and antituberculosis chemical matter toward populating drug discovery pipelines with new lead molecules.

Combinatorial Pathway Engineering for Optimized Production of the Anti‐malarial FR900098

Deciphering the Late Biosynthetic Steps of Antimalarial Compound FR-900098

Combinatorial Pathway Optimization in Escherichia Coli by Directed Co‐evolution of Rate‐limiting Enzymes and Modular Pathway Engineering

Combinatorial Optimization of MEP Pathway to Improve β-Carotene Yield

Cloning, Expression, and Biochemical Characterization of Streptomyces rubellomurinus Genes Required for Biosynthesis of Antimalarial Compound FR900098

Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery

Production of the antimalarial drug precursor artemisinic acid in engineered yeast

Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinic acid

A novel chemogenomic screening platform for scalable antimalarial drug target identification

Combinatorial biosynthesis of novel aminoglycoside antibiotics via pathway engineering

Breaking Boundaries in Malaria Research: Design of a Genetic Tool for High-Throughput Gametocidal Drug Screening

Generation of Fluorinated Amychelin Siderophores Against Pseudomonas Aeruginosa Infections by a Combination of Genome Mining and Mutasynthesis

Structure-guided Design and Biosynthesis of a Novel FR-900098 Analogue As a Potent Plasmodium Falciparum 1-Deoxy-d-xylulose-5-phosphate Reductoisomerase (dxr) Inhibitor

Development and Optimization of a Novel 384-Well Anti-Malarial Imaging Assay Validated for High-Throughput Screening

Compartmentalized Metabolic Engineering for Artemisinin Biosynthesis and Effective Malaria Treatment by Oral Delivery of Plant Cells

Leveraging thePlasmodium falciparum esterase repertoire to design parasite-specific prodrugs

Combinatorial engineering reveals shikimate pathway bottlenecks in para-aminobenzoic acid production in Pseudomonas putida

Mixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets

Experimental design-aided systematic pathway optimization of glucose uptake and deoxyxylulose phosphate pathway for improved amorphadiene production

Increased artemisinin production in Artemisia annua L. by co-overexpression of six key biosynthetic enzymes

Unveiling Potential Repurposed Drug Candidates for Plasmodium falciparum through In Silico Evaluation: A Synergy of Structure-based Approaches, Structure Prediction, and Molecular Dynamics Simulations